NovoEight¨ provides long-term reduction of bleeding in people with haemophilia A

Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight¨ (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight¨ demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.

<OBJECT CLASSID="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" CODEBASE="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=10,0,0,0" WIDTH="320" HEIGHT="283" ID="FLVPlayer" ALIGN=""> <PARAM NAME="movie" VALUE="http://sas-origin.onstreammedia.com/origin/sprucePlayer2.swf?skinName=http://sas-origin.onstreammedia.com/origin/spruceskin2&PVW=320&VH=240&CPH=43&vidURL=rtmp://qps-Flash.OnstreamMedia.com/ondemand/FlashDMSP/multivu_archive/OVD/71400529_Chapter%203_NovoEight.flv&logo=0&autoPlay=False" /> <PARAM NAME="salign" VALUE="lt" /> <PARAM NAME="quality" VALUE="high" /> <PARAM NAME="scale" VALUE="noscale" /> <PARAM NAME="bgcolor" VALUE="#ffffff" /> <PARAM NAME="allowFullScreen" VALUE="true" /> <EMBED SRC="http://sas-origin.onstreammedia.com/origin/sprucePlayer2.swf?skinName=http://sas-origin.onstreammedia.com/origin/spruceskin2&PVW=320&VH=240&CPH=43&vidURL=rtmp://qps-Flash.OnstreamMedia.com/ondemand/FlashDMSP/multivu_archive/OVD/71400529_Chapter%203_NovoEight.flv&logo=0&autoPlay=False&bufferTime=" quality="high" scale="noscale" bgcolor="#ffffff" width="320" height="283" name="FLVPlayer" salign="LT" type="application/x-shockwave-flash" allowFullSCreen="true" pluginspage="http://www.macromedia.com/go/getflashplayer" /> </OBJECT>